GlassScriptPhysician profile
Debra Ann Rill
NPI 1295862001
$3,062.77
in general payments reported to CMS, 2019-2025
22 companies · $378 in 2025
The $378 reported for 2025 was more than what 89% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $561 · 2023: $725 · 2024: $768 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $474.47 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $429.49 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $393.88 | 2022-2024 | Jornay Pm |
| Kaleo, INC. | $282.92 | 2021-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $264.97 | 2021-2025 | Bexsero, Pediarix |
| Sanofi Pasteur INC. | $152.22 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $125.90 | 2021-2025 | Qelbree, Qelbree |
| Alexion Pharmaceuticals, INC. | $112.50 | 2024-2025 | Koselugo, Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $110.76 | 2021-2022 | |
| Pfizer INC. | $95.67 | 2021-2023 | |
| Seqirus USA INC | $91.16 | 2022-2023 | Flucelvax Quadrivalent |
| Adlon Therapeutics L.P. | $83.51 | 2021 | |
| Cranial Technologies, INC | $73.32 | 2023-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $62.32 | 2024-2025 | |
| Tris Pharma INC | $59.94 | 2022-2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $47.81 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $44.21 | 2024-2025 | Voxzogo 1.2mg |
| Tempus Ai, INC | $42.45 | 2024 | |
| Verrica Pharmaceuticals INC. | $42.06 | 2024 | Ycanth |
| Phadia US INC. | $32.27 | 2023-2025 | Immunocap |
| Neurelis, INC. | $24.59 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Rill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.